Esketamine + Esketamine Hydrochloride + Ketamine Hydrochloride for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Aug 2023: Trial registered, NCT05973851
  2. 31 Aug 2024: Trial started, NCT05973851

The trials

NCT05973851: The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

State
Under way
Phase
Phase 3
People
418 planned
Started
31 Aug 2024
Primary completion
30 Jun 2028
Arms
Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray
Results
None posted
  1. 3 Aug 2023: Trial registered
  2. 31 Aug 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.